Stay updated on Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe Czech location/region naming for “Olomouc Region” was updated from a different (Czech-language) form to a new display form, while keeping the same place and postal code. The page also reflects an update to the site build/revision version string.SummaryDifference0.1%

- Check28 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check57 days agoChange DetectedThe site revision was updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check64 days agoChange DetectedThe page now displays Revision: v3.4.3, replacing Revision: v3.4.2.SummaryDifference0.0%

- Check93 days agoChange DetectedRevision: v3.4.2 was added to the page; the funding-status notice about a lapse in government funding and the previous Revision: v3.4.1 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check100 days agoChange Detected- The page now displays a site-wide notice about government funding status and NIH Clinical Center operations, and the revision has been updated from v3.4.0 to v3.4.1.SummaryDifference0.2%

Stay in the know with updates to Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page.